Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AquaCelle Fish Oil Ethyl Ester is a specialized omega-3 fatty acid formulation developed by RDC Clinical. It contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in their ethyl ester forms, integrated with the AquaCelle self-emulsifying delivery system (SEDS). This delivery technology is designed to enhance the bioavailability and gastrointestinal absorption of these lipophilic compounds, which are typically poorly absorbed in the absence of a high-fat meal. The formulation is primarily studied for its pharmacokinetic profile and its potential to optimize omega-3 uptake for the management of hypertriglyceridemia and the reduction of cardiovascular disease risk.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on omega-3-acid ethyl esters (RDC Clinical).